Posted by Michael Wonder on 05 Oct 2021
AZD7442 request for emergency use authorisation for COVID-19 prophylaxis filed in US
5 October 2021 - Filing includes data from PROVENT Phase 3 trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine).
AstraZeneca has submitted a request to the US FDA for an emergency use authorisation for AZD7442, its long-acting antibody combination, for prophylaxis of symptomatic COVID-19.
